Dear editor and reviewer:

Thank you very much for your decision and comments on our manuscript. Your comments are of great significance for us to improve the quality of the manuscripts. We have read your comments carefully and tried our best to improve and made some changes in the manuscript. A revised manuscript has been resubmitted. Now in this reply, we will response the reviewer's comments point by point.

Reviewer's code: 05465429

1. DISCUSSION: line 315 the term "systematic" should be obviated.

Thank you very much for your valuable advice. We read the part of Discussion carefully and found that the word was really out of place here. According to your opinion, this word has been deleted.

Reviewer's code: 05238069

1. The abstract content is complex, some of which can be described in 'introduction', and the statistical contents involved should be summarized briefly.

Thank you very much for your professional advice. We have read the abstract carefully several times. In accordance with your suggestion, its content has been summarized briefly. A lot of complicated statistical content was deleted, and only the more important description was left. In addition, we modified the format of the abstract section according to the requirements. The abstract before and after the modification is as follows:

Before:

Angiosarcoma is a highly malignant soft tissue sarcoma derived from vascular endothelial cells that mainly occurs in the skin and subcutaneous tissues. Small-intestinal angiosarcoma is rare and has a poor prognosis. We reported a primary multifocal ileal angiosarcoma case and

analyzed previously reported cases to improve the understanding of small intestinal angiosarcoma. Together with our patient, we collected 82 cases. Angiosarcoma of the small intestine is more likely to occur in men with a male-to-female ratio of 2.04:1. The patients' mean age was 63.28 years. Gastrointestinal bleeding, anemia, abdominal pain, weakness, and weight loss were the common symptoms. The diagnosis of small-intestinal angiosarcoma relies on morphological features and immunohistochemistry. CD31, CD34, VIII, ERG, Fli-1, and vWF are valuable diagnostic markers. Small-intestinal angiosarcoma most commonly occurs in the jejunum, followed by the ileum and duodenum. Angiosarcoma is prone to metastasis, and at least 56.5% of collected primary cases have definite distant metastasis. Radiation and toxicant exposure are risk factors for angiosarcoma. The average radiation dose is 48.03 ± 14.18 Gray, and the duration from exposure to diagnosis is 16.12 ± 10.05 years, with a range of 7-45 years. After a definite diagnosis of small-intestinal angiosarcoma, the survival time of patients ranged from 3 days to 3 years. The mean and median survival time were 8 month and 3 months, respectively. Kaplan-Meier survival analysis showed that age, infiltration depth, chemotherapy, and the number of small intestinal segments invaded by tumor lesions were prognostic factors for small intestinal angiosarcoma (p<0.05). Multivariate COX regression analysis showed that chemotherapy and surgery significantly improved patient prognosis. Angiosarcoma should be considered for unexplained melena and abdominal pain, especially in older men and in patients with a history of radiation exposure. Prompt treatment, including surgery and adjuvant chemotherapy, is essential for prolonging patients' survival.

After:

BACKGROUND

Angiosarcoma is a highly malignant soft-tissue sarcoma derived from vascular endothelial cells that mainly occurs in the skin and subcutaneous tissues. Small -intestinal angiosarcomas are rare, and the prognosis is poor.

CASE SUMMARY

We reported a case of primary multifocal ileal angiosarcoma and analyze previously reported cases to improve our understanding of small intestinal angiosarcoma. Small intestinal

angiosarcoma is more common in elderly and male patients. Gastrointestinal bleeding, anemia, abdominal pain, weakness, and weight loss were the common symptoms. CD31, CD34, VIII, ERG, Fli-1, and vWF are valuable immunohistochemical markers for the diagnosis of small-intestinal angiosarcoma. Small-intestinal angiosarcoma most commonly occurs in the jejunum, followed by the ileum and duodenum. Radiation and toxicant exposure are risk factors for angiosarcoma. After a definite diagnosis, the mean and median survival time were 8 mo and 3 mos, respectively. Kaplan–Meier survival analysis showed that age, infiltration depth, chemotherapy, and the number of small intestinal segments invaded by tumor lesions were prognostic factors for small intestinal angiosarcoma. Multivariate Cox regression analysis showed that chemotherapy and surgery significantly improved patient prognosis.

CONCLUSION


Angiosarcoma should be considered for unexplained melena and abdominal pain, especially in older men and patients with a history of radiation exposure. Prompt treatment, including surgery and adjuvant chemotherapy, is essential to prolonging patient survival.

2. The journal requests author(s) must submit the related formal ethics documents that were reviewed and approved by their local ethical review committee.

Thanks for your kind reminder. This study has passed the ethical review of The First Affiliated Hospital of Lanzhou University and informed consent was obtained from the patient's family. We can provide the ethical review number and the informed consent signed by the patient' family at the time of hospitalization. However, because of epidemic lockdown, we were unable to provide written ethics documents at the moment. The study protected patient privacy and did not cause any harm to patient. After the epidemic is unsealed, other supporting documents can be added.

Ethical review number: LDYYLL2022-484

Written informed consent:



3. In the line of 54, "month" should change with "months".

We are very sorry for our negligence and thanks for your correction. This mistake has been corrected.

4. The quantity of references is too much, which should be simplified.

Thanks for your comments. This study has two main objectives, one is to present rare case, and the other is to provide a comprehensive review and analysis of this disease. In order to make the statistical results more reliable, we included all the reported cases that we searched, including 76 references and 82 cases. Therefore, the quantity of cited references had to be large. According to your suggestion, we read these literatures carefully and tried to cite as few literatures as possible in manuscript. And we finally reduced the number of references from 90 to 81. We hope you can understand and we would appreciate it.

5. Now, molecular findings might be proved valuable as targets of an immunotherapeutic approach, constituting a promising alternative treatment of angiosarcoma. Hence, molecular finding of the patient should be recommended.

Thank you very much for your professional comments, which are very important to improve the quality of our manuscript. Molecular targeted therapy is indeed a key point that has to be mentioned in tumor treatment. In fact, we recommended the patient undergo genetic testing to allow for the selection of precisely targeted therapy. However, due to the patient's older age and family financial difficulties, they refused and chose to be discharged after surgery. This is indeed a major defect of this case report. In addition, the published case reports of small intestinal angiosarcoma are also lacking genetic testing. To make up for this deficiency. We reviewed the relevant literature to supplement the research progress of molecular targeted therapy in angiosarcoma. In general, most of the current studies have focused on cutaneous angiosarcoma, and there is a lack of clinical trials on small intestinal angiosarcoma. However, with the progress of research and the emphasis on gastrointestinal angiosarcoma, we believe that molecular targeted therapy will make a great contribution to the treatment of this disease. We also hope that our added description of molecular targeted therapy for angiosarcoma will make clinicians pay attention to molecular findings and targeted therapy for small intestinal angiosarcoma. The added content of molecular targeted therapy in the discussion section is shown below:

With the development and clinical application of molecular targeted drugs, molecular targeted therapy for tumors has become a research hotspot in medical oncology. Studies have shown that vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are highly expressed in angiosarcoma. VEGF and VEGFR inhibitors or multi-tyrosine kinase inhibitors, including bevacizumab and pazopanib, are potential drug targets for angiosarcoma. Malignant vascular tumors, including angiosarcoma, express high levels of adrenergic receptors. Targeting these receptors with drugs such as protamine inhibited tumor growth in mouse vascular cell lines (80). In addition, a few cases with cutaneous angiosarcoma showed significant responses to checkpoint inhibitors, including pembrolizumab, anti-PD-L1 antibody,

In addition, there are the following points to note.

1. We modified the format of the manuscript as requested by the journal for successful publication.

2. We note that the number of references in case reports is generally controlled at 30 to 60. However, our study has two main objectives, one is to present rare case, and the other is to provide a systematic review and analysis of this disease. In order to make the statistical results more reliable, we included all the reported cases that we searched, including 76 references and 82 cases. Therefore, the number of references we finally cited reached 81. We hope you can understand and we would appreciate it. In addition, 15 of the cited references were not indexed on PubMed. In accordance with the regulations, we provided the printed copy of the first page and uploaded them as Supplementary Material. The PDF files were named in accordance with the order in which the reference was cited in the manuscript.

3. Moreover, although this is a serious problem because the manuscript has been reviewed, we are wishing to add Mr. Hou as an extra author to the manuscript. Xu-Dong Hou is the patient's chief surgeon and he contributed a lot to the patient's entire treatment and follow-up process. In revison process, he did a great job for the expansion of literature review so as to provide a deeper insight into the related work. After consultation among all the authors, we decide to add Xu-Dong Hou as the ninth author. If you give us this chance, we will be grateful.

Thanks for your time and attention. The above is the main modification and improvement we have made to the manuscript. We sincerely hope you find our responses and modifications satisfactory and that this manuscript is accepted to publication.

Sincerely yours, Qinghong Guo